HER2, ALK, EGFR, ROS1, NTRK. These keywords have been frequent visitors in articles on anticancer drugs recently.

With the discovery that effective anticancer treatments differ depending on the patient’s genetic mutation status, personalized treatments that target specific genes of each individual are being introduced. And the development of precision medicine has heralded the paradigm shift of cancer treatments to ‘gene-specific treatment’ from ‘diseases-specific treatment.’

Amid rising expectations, the first anticancer treatment that targets the MET gene was newly introduced to Korea. The treatment, Novartis’ ‘Tabrecta (capmatinib),’ was authorized for the treatment of metasta